Datar, Manasi
Ramakrishnan, Saranya
Montgomery, Elizabeth
Coca, Steven G.
Vassalotti, Joseph A.
Goss, Thomas
Article History
Received: 12 January 2021
Accepted: 27 April 2021
First Online: 17 May 2021
Declarations
:
: All methods were carried out in accordance with guidelines and regulations from Good Clinical Research Practice (GCP).
: N/A as this manuscript does not include details, images, or videos relating to an individual person.
: MD: Employee of Boston Healthcare Associates, Inc. which received has research funding from Renalytix AI, Inc., Relypsa, Vascular Therapies, and Proteomics International;SR: Employee of Boston Healthcare Associates, Inc. which received has research funding from Renalytix AI, Inc., Relypsa, Vascular Therapies, and Proteomics International;EM: NoneSGC: Consultant to Renalytix AI, Inc. Received financial compensation from CHF Solutions, Boehringer-Ingelheim, Takeda, pulseData, Relypsa, Bayer, inRegen, and Quark;JAV: Serves as a member of the Scientific Advisory Board at Renalytix AI, Inc.TFG: Employee of Boston Healthcare Associates, Inc. which received research funding from Renalytix AI, Inc., Relypsa, Vascular Therapies, and Proteomics International